We describe herein a case of CD8‐positive peripheral T cell lymphoma (CD8+ PTCL) after long‐term PD‐1 blockade by nivolumab for advanced lung adenocarcinoma, and discuss the possibility of a relationship between ICI treatment and development of CD8+ PTCL. This evidence concerns the gene CD8A and lung adenocarcinoma.